AGENDA

National Collegiate Athletic Association
Doping, Drug Testing, and Drug Education Task Force

Christine Grant Ballroom B
Indianapolis, Indiana

July 15-16, 2013

1. Welcome and introductions. (Brian Hainline)
   a. Task force members.
   b. Purpose of task force.
   c. Timeline of initiatives.

2. History of doping and drug testing in sport. (Gary Wadler)

3. Ethical concerns of doping and drug testing in sport. (Tom Murray)

4. History of NCAA drug testing program. (Frank Uryasz)

5. NCAA drug and alcohol education. (Mary Wilfert)
   a. Recreational drugs.
   b. Performance enhancing drugs.

6. Definitions and discussion.
   a. Performance enhancing drugs. (John Lombardo)
   b. Recreational drugs. (Don Vereen)
   c. Potential overlap: Real vs. rationalized. (Bill Bock and Hainline)
      (1) Stimulants.
      (2) Marijuana.
      (3) Opiates.
      (4) Alcohol.
7. NCAA-specific issues: overview.
   a. Committee on Competitive Safeguards and Medical Aspect of Sports (CSMAS). (Andrew Smith)
   b. Divisions I, II, and III. (Harris Pastides, Denisha Hendricks, Jeff Martinez)

8. NCAA-specific issues: drug testing program information and data.
   a. Testing processes. (Andrea Wickerham)
      (1) Protocol.
      (2) Lab subcontracts.
      (3) Other considerations.
   b. Testing data and program elements. (Wilfert)
      (1) Numbers.
      (2) Penalties.
      (3) Appeals and medical exceptions.

9. Deterrence vs. detection.
   a. Developing a deterrence model. (Larry Bowers)
   b. Evaluating effectiveness of deterrence. (David Wyrick)
      (1) Performance enhancing drugs and doping methods.
      (2) Alcohol and recreational drugs.

10. Developing an ideal intercollegiate Doping, Drug Education and Drug-Testing Program: NCAA vs. Member Institutions. (Hainline/Group)
    a. Educational approaches. (True Sport Representative and Wyrick)
       (1) Performance drugs.
(2) Recreational drugs.

b. **Testing considerations.** (Bock and Wickerham)

   (1) Performance drugs.

   (2) Recreational drugs.

c. Lab standards. (Tony Butch)

d. Special considerations. (Bowers and Wadler)

   (1) Caffeine.

   (2) Growth hormone.

   (3) Blood doping.

   (4) Manipulation.

   (5) Local anesthetics.

e. Neuro-enhancements. (William Graf)

f. Other considerations. (Robert Cabry and Mark Chassay)

11. Partnerships. (Jim Whitehead)

   a. **Member institutions and national office departments.**

   b. **Coaches associations.**

   c. **Professional leagues.**

   d. **Sports medicine.**

      (1) American College of Sports Medicine (ACSM).

      (2) American Medical Society for Sports Medicine (AMSSM).

      (3) National Athletic Trainers Association (NATA).

e. **Governing bodies.**
(1) National Federation of State High School Associations (NFHS).

(2) National Governing Bodies and Sports Federations.

f. **Testing agencies.**

(1) United States Anti-Doping Agency (USADA).

(2) World Anti-Doping Agency (WADA).

(3) Drug Free Sport.

g. **Partnership for Clean Competition Drug Testing Research Collaborative.**

h. **Government.**

(1) Centers for Disease Control and Prevention (CDC).

(2) National Institute on Alcohol Abuse and Alcoholism (NIAAA).

(3) Substance Abuse and Mental Health Services Administration (SAMHSA).

12. **Strategic Elements -- Small group work referencing worksheets --** Groups will be organized to represent diverse perspectives with the charge to recommend strategies for a comprehensive approach.

13. **Large group discussion, summaries and next steps.** (Hainline)

13. **Adjournment.**